[
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) Presents Promising KEYTRUDA Trial Data at AACR 2025 Meeting",
    "summary": "Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, contributing to a 6% price increase over the past week. The supplemental Biologics License Application under FDA review further highlights KEYTRUDA's significance in Merck's portfolio. This comes amid a broader market upswing, as the S&P 500 and Nasdaq climbed overall. While Merck's earnings were...",
    "url": "https://finnhub.io/api/news?id=c94d29b7cc32573e72f833921f02c8174d23ee12f84e32c1fd30762455c352a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745862176,
      "headline": "Merck (NYSE:MRK) Presents Promising KEYTRUDA Trial Data at AACR 2025 Meeting",
      "id": 134131060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, contributing to a 6% price increase over the past week. The supplemental Biologics License Application under FDA review further highlights KEYTRUDA's significance in Merck's portfolio. This comes amid a broader market upswing, as the S&P 500 and Nasdaq climbed overall. While Merck's earnings were...",
      "url": "https://finnhub.io/api/news?id=c94d29b7cc32573e72f833921f02c8174d23ee12f84e32c1fd30762455c352a7"
    }
  },
  {
    "ts": null,
    "headline": "Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion",
    "summary": "SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The acquisition price translates to an equity value of around $3.9 billion and an enterprise value of $3.4 billion (3.0 billion euros), based on SpringWorks' cash position of $461.9 million as of December 31, 2024. As per media reports in February, Merck Germany reacted to press reports and confirmed advanced",
    "url": "https://finnhub.io/api/news?id=33500cdb573700231166731f6ddbccb73201ae889848d672ede5a4b46c83902d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745857078,
      "headline": "Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion",
      "id": 134117551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The acquisition price translates to an equity value of around $3.9 billion and an enterprise value of $3.4 billion (3.0 billion euros), based on SpringWorks' cash position of $461.9 million as of December 31, 2024. As per media reports in February, Merck Germany reacted to press reports and confirmed advanced",
      "url": "https://finnhub.io/api/news?id=33500cdb573700231166731f6ddbccb73201ae889848d672ede5a4b46c83902d"
    }
  },
  {
    "ts": null,
    "headline": "Temu, Tesla prices, Merck KGaA deal: Trending Tickers",
    "summary": "Online retailer Temu — owned by PDD Holdings (PDD) — aims to raise prices amid tariffs, while Tesla (TSLA) raises its EV prices in Canada and Merck KGaA (MRK) seeks to acquire SpringWorks Therapeutics (SWTX) in a $3.9 billion deal. Catalysts host Madison Mills and Ritholtz Wealth Management chief market strategist Callie Cox weigh in on these top stocks. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
    "url": "https://finnhub.io/api/news?id=dcbcab0d70f03d3793e1cbcb6241cc71a49390224680fef1fafdefd163fe21bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745850938,
      "headline": "Temu, Tesla prices, Merck KGaA deal: Trending Tickers",
      "id": 134114996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Online retailer Temu — owned by PDD Holdings (PDD) — aims to raise prices amid tariffs, while Tesla (TSLA) raises its EV prices in Canada and Merck KGaA (MRK) seeks to acquire SpringWorks Therapeutics (SWTX) in a $3.9 billion deal. Catalysts host Madison Mills and Ritholtz Wealth Management chief market strategist Callie Cox weigh in on these top stocks. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
      "url": "https://finnhub.io/api/news?id=dcbcab0d70f03d3793e1cbcb6241cc71a49390224680fef1fafdefd163fe21bb"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck & Co., Inc. (MRK) the Most Profitable Blue Chip Stock to Buy Now?",
    "summary": "We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most profitable blue chip stocks to buy now. Blue chip stocks are large, financially stable companies with strong market presence, consistent […]",
    "url": "https://finnhub.io/api/news?id=676fca35aa372c62a45b73b8266bb9482879c9b6c9f19f181efb352e00c1706d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745846375,
      "headline": "Is Merck & Co., Inc. (MRK) the Most Profitable Blue Chip Stock to Buy Now?",
      "id": 134115165,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most profitable blue chip stocks to buy now. Blue chip stocks are large, financially stable companies with strong market presence, consistent […]",
      "url": "https://finnhub.io/api/news?id=676fca35aa372c62a45b73b8266bb9482879c9b6c9f19f181efb352e00c1706d"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?",
    "summary": "We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.",
    "url": "https://finnhub.io/api/news?id=35d730402ed9f4087146ec280eb5f21d85d4e4554baceb8bcfbaec284ce6824c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745840880,
      "headline": "Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?",
      "id": 134115166,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.",
      "url": "https://finnhub.io/api/news?id=35d730402ed9f4087146ec280eb5f21d85d4e4554baceb8bcfbaec284ce6824c"
    }
  },
  {
    "ts": null,
    "headline": "Merck - KEYTRUDA as Perioperative Treatment with Standard of Care Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone",
    "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA , Merck's anti-PD-1 therapy, as a perioperative...",
    "url": "https://finnhub.io/api/news?id=150eea4eb0d22d76db138728fb3b028ecba852ae55a8762c3c8af33249b0d02c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745840297,
      "headline": "Merck - KEYTRUDA as Perioperative Treatment with Standard of Care Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone",
      "id": 134115478,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA , Merck's anti-PD-1 therapy, as a perioperative...",
      "url": "https://finnhub.io/api/news?id=150eea4eb0d22d76db138728fb3b028ecba852ae55a8762c3c8af33249b0d02c"
    }
  },
  {
    "ts": null,
    "headline": "2 Must-Own Dividends At Bargain Basement Prices",
    "summary": "Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios. Read more on MRK and SLB stocks here.",
    "url": "https://finnhub.io/api/news?id=468bfc06dd85ac1e6c9ce17a486ff5869c4fd89c5a0073c009b699ccaa8dc816",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745829060,
      "headline": "2 Must-Own Dividends At Bargain Basement Prices",
      "id": 134113729,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182902629/image_182902629.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios. Read more on MRK and SLB stocks here.",
      "url": "https://finnhub.io/api/news?id=468bfc06dd85ac1e6c9ce17a486ff5869c4fd89c5a0073c009b699ccaa8dc816"
    }
  },
  {
    "ts": null,
    "headline": "Merck: positive results in head & neck cancer",
    "summary": "Merck reports that a Phase 3 trial has shown that Keytruda , used as perioperative treatment for patients with locally advanced head and neck squamous cell carcinoma, has 'significantly' improved...",
    "url": "https://finnhub.io/api/news?id=7514592ab1826a9224e3101de2684a8c478b4128e8421e59e445ea44eca64afc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745813776,
      "headline": "Merck: positive results in head & neck cancer",
      "id": 134112036,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck reports that a Phase 3 trial has shown that Keytruda , used as perioperative treatment for patients with locally advanced head and neck squamous cell carcinoma, has 'significantly' improved...",
      "url": "https://finnhub.io/api/news?id=7514592ab1826a9224e3101de2684a8c478b4128e8421e59e445ea44eca64afc"
    }
  }
]